Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40138-014-0040-z http://scihub22266oqcxt.onion/10.1007/s40138-014-0040-z C4023865!4023865!24855585     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Emerg+Hosp+Med+Rep 2014 ; 2 (2): 126-32 Nephropedia Template TP {{tp|p=24855585|t=2014. Vasodilators in Acute Heart Failure: Review of the Latest Studies |pdf=|usr=}}{{24855585}} gab.com Text Vasodilators in Acute Heart Failure: Review of the Latest Studies JO: Curr Emerg Hosp Med Rep http://www.kidney.de/pget.php?&tw=1&pmid=24855585 #FOAvip Vasodilators play an important role in the management of acute heart failure, particularly when increased afterload is the precipitating cause of decompensation. The time-honored approach to afterload reduction has been largely focused on use of intravenous nitrovasodilators and, when properly dosed, this class of agents does provide substantial symptom relief for patients with acute hypertensive heart failure. Despite this, nitrovasodilators have never been shown to diminish mortality or provide any post-discharge outcome benefit leading to an on-going search for viable and more effective alternatives. While no new vasodilators have been approved for use in acute heart failure since nesiritide more than a decade ago, a number of novel agents have been developed, with some showing significant promise in recent clinical trials. In this review, we summarize the latest study data as it relates to vasodilator therapy and provide a glimpse into the not too distant future state of acute heart failure care. Twit Text FOAVip Vasodilators in Acute Heart Failure: Review of the Latest Studies ????Curr Emerg Hosp Med Rep http://www.kidney.de/pget.php?&tw=1&pmid=24855585 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24855585 #FOAvip English Wikipedia <ref>{{Cite pmid|24855585}}</ref> Vasodilators in Acute Heart Failure: Review of the Latest Studies #MMPMID24855585 Levy PD; Laribi S; Mebazaa A Curr Emerg Hosp Med Rep 2014[Jun]; 2 (2): 126-32 PMID24855585show ga Vasodilators play an important role in the management of acute heart failure, particularly when increased afterload is the precipitating cause of decompensation. The time-honored approach to afterload reduction has been largely focused on use of intravenous nitrovasodilators and, when properly dosed, this class of agents does provide substantial symptom relief for patients with acute hypertensive heart failure. Despite this, nitrovasodilators have never been shown to diminish mortality or provide any post-discharge outcome benefit leading to an on-going search for viable and more effective alternatives. While no new vasodilators have been approved for use in acute heart failure since nesiritide more than a decade ago, a number of novel agents have been developed, with some showing significant promise in recent clinical trials. In this review, we summarize the latest study data as it relates to vasodilator therapy and provide a glimpse into the not too distant future state of acute heart failure care. äVasodilators in Acute Heart Failure: Review of the Latest Studies (epmc).pdf DeepDyve Pubget Overpricing